Evommune drops eczema drug after trial miss

Evommune abandoned its experimental eczema treatment after it failed to meet the primary goal in a mid-stage trial. The setback sent the company shares down 24 percent in aftermarket trading. The firm plans to focus development of the drug on migraine prevention instead.